In line with molecular docking, these two triterpenoids were also among the strongest binding affinities (< − 9.78 kcal/mol) to blood pressure modulate targets AT1R and HSD11B1, emphasizing them as promising pharmacologically contributing drug candidates for mitigating not only DS but also MetS associated hypertension. The gene discussed is HSD11B1; the disease is Dravet syndrome.